Table 5.
TACE + lenvatinib + PD-1 inhibitors (n = 23) | TACE + lenvatinib (n = 32) | TACE + sorafenib (n = 29) | P-value | |
---|---|---|---|---|
Elevated ALT | ||||
At enrolment | 3 (13.04) | 3 (9.38) | 4 (13.79) | .837 |
After treatment discontinuation | 3 (13.04) | 5 (15.63) | 5 (17.24) | .925 |
P-value | 1.000 | .708 | 1.000 | |
Elevated AST | ||||
At enrolment | 3 (13.04) | 4 (12.50) | 5 (17.24) | 1.000 |
After treatment discontinuation | 6 (26.09) | 8 (25.00) | 8 (27.59) | .728 |
P value | .459 | .337 | .530 |
Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; RECIST, modified response evaluation criteria in solid tumors; PD-1, programmed death 1; TACE, transarterial chemoembolization.